The central nervous system accounts for only 2% of the whole body mass but contains almost a quarter of the unesterified cholesterol present in the whole individual. This sterol is largely present in two pools comprised of the cholesterol in the plasma membranes of glial cells and neurons and the cholesterol present in the specialized membranes of myelin. From 0.02% (human) to 0.4% (mouse) of the cholesterol in these pools turns over each day so that the absolute flux of sterol across the brain is only approximately 0.9% as rapid as the turnover of cholesterol in the whole body of these respective species. The input of cholesterol into the central nervous system comes almost entirely from in situ synthesis, and there is currently little evidence for the net transfer of sterol from the plasma into the brain of the fetus, newborn or adult. In the steady state in the adult, an equivalent amount of cholesterol must move out of the brain and this output is partly accounted for by the formation and excretion of 24S-hydroxycholesterol. This cholesterol turnover across the brain is increased in neurodegenerative disorders such as Alzheimer's disease and Niemann±Pick type C disease. Indirect evidence suggests that large amounts of cholesterol also turn over among the glial cells and neurons within the central nervous system during brain growth and neuron repair and remodelling. This internal recycling of sterol may involve ligands such as apolipoproteins E and AI, and one or more membrane transport proteins such as members of the low density lipoprotein receptor family. Changes in cholesterol balance across the whole body may, in some way, cause alterations in sterol recycling and apolipoprotein E expression within the central nervous system, which, in turn, may affect neuron and myelin integrity. Further elucidation of the processes controlling these events is very important to understand a variety of neurodegenerative disorders.
Introduction
For many years, investigators interested in cholesterol metabolism have largely ignored the brain because this organ does not appear to be important in whole-animal sterol economy and apparently does not respond to many of the control mechanisms operative in maintaining sterol homeostasis in most other organs. In the past few years, however, it has become apparent that this disinterest is misguided. Clearly, neurons, like all other cells in the body, must have a continuous supply of unesteri®ed cholesterol, and this sterol must come either from de novo synthesis within the nerve cells or from the uptake of cholesterol from the extracellular environment utilizing speci®c ligands and membrane transporters [1] . Furthermore, the¯ow of sterol through the metabolic machinery of the neurons and glial cells apparently alters the rate of processing of membrane bound proteins such as b-amyloid precursor protein (APP) and the level of expression of extracellular ligands such as apolipoprotein (apo)E within the central nervous system (CNS) [2± 5,6 . . ]. Mutations that affect the synthesis of cholesterol or its movement through the endocytic uptake pathway of neurons lead to profound abnormalities of the CNS and marked neurodegeneration [7 . ±9 . ]. Furthermore, changes in net cholesterol balance across the whole animal may, indirectly, alter sterol balance across the CNS and also contribute to the development of neurodegeneration. Indeed, it has recently been reported that treating humans with agents that block cholesterol synthesis in every organ, including the brain, markedly reduces the incidence of Alzheimer's disease [10 . . ]. These ®ndings illustrate how important it is to have a better understanding of the mechanisms that control cholesterol balance, both across the blood±brain barrier between the plasma and cerebrospinal¯uid and within the CNS between the various neurons and glial cells. This brief review focuses on the new developments that better de®ne these two areas of cholesterol metabolism.
Proteins that control cholesterol flux between organs and across the whole animal Before dealing speci®cally with cholesterol movement through the CNS, it is important to de®ne those proteins that dictate sterol movement through the cytosol of the cell, across the plasma membrane and through the plasma. As shown diagrammatically in Fig. 1 , most cholesterol in the whole animal comes from de novo synthesis in the extrahepatic tissues. This cholesterol apparently moves from the endoplasmic reticulum, through the Golgi and detergent-insoluble glycosphin-golipid-enriched complexes to sterol-rich microdomains in the plasma membrane such as the caveolae. Although some of this sterol then moves laterally into the bulk phase of the membrane, most apparently leaves the cell under the in¯uence of the adenosine triphosphatebinding cassette transporter (ABC) A1 transporter, becomes associated with apoAI, and is esteri®ed by lecithin:cholesterol acyltransferase [11 . ]. A portion of this cholesteryl ester may be transferred by cholesteryl ester transfer protein to an apoB-containing lipoprotein particle that ultimately is cleared by the liver. Alternatively, the remaining cholesteryl ester is directly taken up into the liver utilizing the scavenger receptor class B, type I (SR-BI) transporter [12] . At the same time, lesser amounts of cholesterol are absorbed into the intestinal epithelial cell from the diet, esteri®ed to cholesteryl ester by acyl coenzyme A : cholesterol transferase, and delivered to the liver in the remnants of the chylomicron. After being processed through the coated-pit pathway, this cholesterol mixes with other pools of sterol within the hepatocyte and is partly esteri®ed by acyl coenzyme A : cholesterol transferase. The cholesteryl ester is then incorporated into VLDL and secreted into the plasma. During the metabolism of this very low density particle, a portion of the cholesteryl ester ends up in LDL, and a small fraction of this is cleared into the cells of the extrahepatic tissues utilizing the LDLR present in coated pits [13] . After processing of the LDL particles and hydrolysis of the cholesteryl ester in the lysosomes, this cholesterol is transferred by Niemann± Pick type C protein 1 (NPC1) to the metabolic pathway moving newly synthesized cholesterol to the plasma membrane through the Golgi/detergent-insoluble glycosphingolipid-enriched complexes pathway [14
Several features of this overall scheme of sterol movement in the body warrant emphasis. First, in every species most cholesterol moving out of the extrahepatic This figure shows many of the proteins thought to be utilized in the movement of unesterified cholesterol (C) and cholesteryl ester (CE) among the different organs of the body, and for excretion into the feces as either neutral or acidic sterols. Anatomical regions of cells are shown in italics, the major proteins are enclosed in boxes, and the ligands that bind to the membrane transport proteins are shown in parentheses. In general, the greatest flow of cholesterol through the body is from the sites of synthesis in the extrahepatic tissues, through the plasma to the liver, and from the liver into the bile and, ultimately, the feces. This process requires a variety of membrane transporters and carrier proteins, many of which may also function to move cholesterol across the central nervous system (CNS) and among the glial cells and neurons. 
Net sterol flux across the central nervous system
The ®rst question of importance is whether there is a steady-state¯ux of cholesterol across the mature CNS, and whether the movement of this sterol is regulable, as it is in the other organs of the whole animal. Although quantitative data on this point are limited, calculation of these¯ux rates has been made in three species [21
As shown in Fig. 2 The steady-state cholesterol (C) pools in the whole animal and central nervous system (CNS) are shown for the human, baboon and mouse. Although these pools usually remain constant in size, there is a continuous flux of cholesterol across the whole animal and brain, as well as a constant movement of sterol among the organs of the whole animal ( Fig. 1) and cells of the CNS. The possible transporters involved in this internal recycling through the CNS are shown in the box, whereas the possible ligands involved in this process are given in parentheses. The net flux of cholesterol across the whole animal and CNS is dictated by those proteins that account for cholesterol input into these systems and those proteins that determine the rate of output from these two compartments. ApoAI, apolipoprotein AI; ApoD, apolipoprotein D; ApoE, apolipoprotein E; ApoER2, apolipoprotein E receptor 2; ApoJ, apolipoprotein J; LDLR, LDL receptor; LRP, LDL receptor-related protein; VLDLR, VLDL receptor.
Quantitative data suggest that all, or nearly all, input of cholesterol into the CNS comes from in situ synthesis. Several studies have shown that the absolute rates of sterol synthesis found in the whole brain, and in different regions of the CNS, can account for essentially all cholesterol laid down during brain development [26± 29]. Furthermore, even the mature brain continues to synthesize cholesterol at a constant, albeit a low, rate throughout life [30, 31] . In contrast, direct measurements carried out in vivo have failed to show any LDLcholesteryl ester or HDL-cholesteryl ester uptake from the plasma into any region of the brain in the adult animal or even during fetal and newborn brain development [32, 33] . These data support the conclusion, therefore, that essentially all cholesterol input into the CNS comes from de novo synthesis (Fig. 2) . Similarly, the input of cholesterol into the whole animal largely comes from in situ synthesis in the extrahepatic tissues, although exogenous sterol can contribute to this input if cholesterol is present in the diet (Fig. 1) . However, there is one important caveat. There could still be the uptake of small amounts of plasma lipoprotein-cholesterol into the CNS at rates too low to be detected by current methods. This is a critically important issue because feeding cholesterol, and raising the plasma lipid level, is associated with a number of metabolic changes in the brain. Whether these changes are signalled by an increase in cholesterol input into the CNS from the plasma or by some other mechanism remains unknown.
Important new information has also appeared concerning the nature of the processes that dictate cholesterol output from the CNS. Recently, a sterol hydroxylase capable of converting cholesterol to 24S-hydroxycholesterol has been cloned and shown to represent a new cytochrome P450 subfamily (CYP46). This enzyme is predominantly expressed in the brain and, more particularly, within many, but not all, neurons [34
. . ]. Importantly, the 24S-hydroxycholesterol that is formed can cross the blood±brain barrier and enter the plasma, and studies in humans have con®rmed that most of the oxysterol that appears in the circulation comes from the brain [22] . The 24-hydroxylation of cholesterol, and its subsequent movement out of the CNS, may thus be an important pathway for the output of sterol from the brain. However, the rate of output of 24S-hydroxycholesterol is less than the input of cholesterol from synthesis [35] . Furthermore, under conditions in which the pool of cholesterol in the CNS remains constant, the rate of sterol synthesis is reduced only approximately 40% when activity of this 24-hydroxylase is deleted from the animal. The formation and excretion of 24S-hydroxycholesterol is thus a major, but not the only, pathway for cholesterol output from the CNS. For comparison, cholesterol output from the whole animal also partly depends upon the formation of oxysterols such as 7a-hydroxycholesterol and 27-hydroxycholesterol, but the major pathway for cholesterol output utilizes proteins such as SR-BI, ABCA1 and ABCB4 to excrete cholesterol itself into the feces [19 . ,20
. ,36 . ]. Whether one or more of these latter proteins also accounts for the remainder of the cholesterol output from the CNS remains to be established.
Net sterol flux among the cells of the central nervous system
The second major question of importance is whether there is a signi®cant movement of cholesterol among the different types of glial cells and neurons within the CNS and, furthermore, which proteins might be involved in this recycling process (Fig. 2) . Older data obtained in nerves from the peripheral nervous system implicated the LDL receptor and apoE in the process of nerve repair and growth. After damage to the sciatic nerve, for example, cholesterol from degenerating myelin and plasma membranes is esteri®ed and sequestered in Schwann cells and local macrophages. With time, these macrophages secrete increased amounts of apoE, apoAI enters the region from the circulating plasma, and LDL receptors become abundantly expressed at the nerve tips [1,37,38]. These ®ndings imply that during repair, cholesterol derived from the damaged nerve cell and myelin is recycled utilizing apoE as the ligand and the LDL receptor as the transport protein. A similar uptake of apoE-associated cholesterol has been described in nerve cells from the CNS, but the fact that this transport is partly blocked by receptor-associated protein suggests that in this case LDL receptor-related protein (LRP), rather than the LDL receptor, is responsible for uptake of the apoE-sterol complex [39±41].
Such data imply that the recycling of cholesterol may continuously take place within the CNS, and may be critical for neuron repair and remodelling, even in the adult brain. It is not certain, however, which proteins are involved in this process. In contrast to the cells of the rest of the body that primarily use the LDL receptor for the uptake of lipoprotein-cholesterol (Fig.  1) , cells of the brain express many transporters of the LDL receptor family, including LDL receptor itself, LRP, VLDL receptor, apoE receptor 2, megalin and others (Fig. 2) [42±45]. These proteins are found in both neurons and glial cells. The brain also synthesizes a number of ligands, including apoE, apoD, and apoJ [45, 46, 47 . ,48,49 . ,50 . ]. In addition, apoAI is found in the cerebrospinal¯uid, but is synthesized elsewhere and apparently ®ltered across the blood±brain barrier into the CNS. Notably, apoB 100 is not found in the CNS [51] .
Despite the advances in this area, it has been dif®cult to demonstrate directly the recycling of cholesterol in the intact CNS. One approach to this problem has been to take advantage of animals with a mutation in NPC1 (Fig.  1) . Because all transporters of the LDL receptor family are apparently localized to coated pits, any apoEassociated cholesterol taken up into neurons should be trapped within the endosome/lysosome compartment if such cholesterol recycling actually occurs in the brain. NPC1 is expressed in the cells of every organ in the body, including glial cells and neurons in the CNS [52,53
. ,54
. . ]. This accounts for the fact that because animals homozygous for the mutant NPC1 transport LDL-cholesteryl ester and chylomicron-cholesteryl ester into the cells normally, they accumulate cholesterol in every organ outside of the CNS in proportion to the amount of lipoprotein-cholesteryl ester taken up by each tissue through the coated-pit pathway (Fig. 1) ]. The critical ®nding, therefore, is that substantial amounts of cholesterol accumulate in every region of the CNS, as in all other organs, in newborn mice with this mutation [21 . . ,57]. This observation provides the ®rst direct evidence that in vivo there is substantial recycling of cholesterol within the CNS through the coated-pit pathway.
The identi®cation of the proteins involved in this process, however, is less certain. Although in-vitro experiments with nerve cells from either the peripheral or CNS strongly suggest important roles for apoE and LDL receptor or LRP in this recycling process, studies carried out in vivo are more ambiguous. For example, there is a marked decrease in HDL-cholesteryl ester in the plasma of mice lacking apoAI, a marked increase in circulating LDL-cholesteryl ester in animals with no LDL receptor activity, and a signi®cant elevation of remnant particles in animals lacking apoE [32, 58, 59 ]. In contrast, there are no gross abnormalities in CNS development or function in these three groups of knockout animals. Furthermore, in vivo, repair of damage to peripheral nerves occurs normally in the absence of both apoAI and apoE [60, 61] . Similarly, the deletion of either apoE or LDL receptor from the CNS does not prevent the accumulation of cholesterol in the brains of animals with non-functional NPC1 nor prolongs their lives [21 . . ,62
. . ]. The deletion of apoAI, apoE or LDL receptor thus results in the predicted phenotypes with respect to changes in circulating lipoprotein patterns and rates of lipoprotein-cholesteryl ester uptake into the various organs of the body (Fig.  1) . However, even though both peripheral and central nerves take up cholesterol through the coated-pit pathway that requires functional NPC1 activity, deletion of the likely ligands, apoAI and apoE, and the likely transporter, LDL receptor, fails to alter this cholesterol recycling process in either the peripheral or CNS [60, 61, 62 . . ,63].
The likely explanation for these ®ndings is that there is considerable redundancy in these cholesterol transport processes systemically, as well as in the CNS. For example, the LDL receptor is normally involved in clearing both LDL-cholesteryl ester (utilizing the ligand apoB 100 ) and the remnants of VLDL and chylomicron (utilizing the ligand apoE) from the plasma. However, when the LDL receptor is deleted, LRP takes over the clearance of the apoE-containing remnants, but not the apoB 100 -containing LDL particles [16, 64] . Similarly, within the CNS, deletion of either VLDL receptor or apoE receptor 2 alone does not affect the gross development of the brain, although there are some subtle abnormalities in neural organization. However, when both receptors are deleted there is a marked developmental defect in neuronal layering in the cerebrum and cerebellum [65 . . ,66]. Therefore, in the absence of LDL receptor activity in the CNS, one of the other transporters such as LRP or VLDL receptor may take over this transport function. Similarly, in the absence of apoE some other ligand such as apoJ or apoD may partly substitute as a carrier of cholesterol. Further progress in this area may require the creation of animals with the deletion of multiple proteins.
Cholesterol balance in the brain and diseases of the central nervous system
There are now a number of instances in which disordered cholesterol metabolism in the CNS may be etiologically related to the onset of neurological disease. In the Smith±Lemli±Opitz syndrome, for example, the marked abnormalities in brain development and function probably re¯ect the fact that the major input of cholesterol into the CNS comes from de novo synthesis, and such synthesis is defective in this syndrome [67, 68] . That apoE may be important for cholesterol recycling within the CNS probably explains the subtle abnormalities seen in the brain in the absence of this protein and the poor prognosis for recovery of neurological function after head trauma in individuals carrying the apoE4 isoform [58, 69] . The defect in intracellular cholesterol movement through the coated-pit pathway in both glial cells and neurons may be etiologically important in the progressive neurodegeneration seen in Niemann±Pick type C disease [8 . ,21 . . ,62
. . ]. Finally, the observations that changes in cholesterol balance across cells affects both the rate of processing of proteins such as APP and the level of apoE in the CNS may explain the ®ndings that cholesterol feeding enhances the rate of neuritic plaque formation in the brain, whereas the administration of inhibitors of cholesterol synthesis apparently markedly reduces the prevalence of Alzheimer's disease [2, 5, 6 . . ,10 . . ,70,71 . . , 72, 73] .
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Conclusion
During the past few years there have thus been a number of important discoveries related to proteins that play important roles in cholesterol movement through the body, in general, and across the CNS, in particular. However, during this same period, it has also become clear that additional information is required in two key areas related to cholesterol metabolism in the CNS. 2892±2897. This important paper demonstrates that expression of apoE3 and apoE4 is required for neuritic plaque formation in a mouse model of Alzheimer's disease. ApoE4 expression resulted in a significantly greater amyloid b-peptide burden and plaque formation than apoE3.
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